Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
University of Nebraska
EMD Serono
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University College, London
Memorial Sloan Kettering Cancer Center
Cellectar Biosciences, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
Degron Therapeutics Co.
Petrov, Andrey
City of Hope Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Alabama at Birmingham
University of Alabama at Birmingham
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Barbara Ann Karmanos Cancer Institute
Blueprint Medicines Corporation
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Prelude Therapeutics
Istari Oncology, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
University of Nebraska
Sumitomo Pharma America, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SCRI Development Innovations, LLC
Canadian Cancer Trials Group
Columbia University
Duke University
Case Comprehensive Cancer Center
Duke University
Quadriga Biosciences, Inc.
City of Hope Medical Center
Stanford University
Jonsson Comprehensive Cancer Center
Duke University
Duke University
Biogen
Jonsson Comprehensive Cancer Center